Matinas BioPharma Holdings Inc. (AMEX:MTNB) price closed higher on Monday, September 13, jumping 27.12% above its previous close.
A look at the daily price movement shows that the last close reads $0.83, with intraday deals fluctuated between $0.89 and $1.10. The company’s 5Y monthly beta was ticking 2.62. Taking into account the 52-week price action we note that the stock hit a 52-week high of $2.22 and 52-week low of $0.67. The stock added 39.07% on its value in the past month.
Matinas BioPharma Holdings Inc., which has a market valuation of $196.01 million, is expected to release its quarterly earnings report Nov 04, 2021 – Nov 08, 2021. Analysts tracking MTNB have forecast the quarterly EPS to shrink by -0.03 per share this quarter, while the same analysts predict the annual EPS to hit -$0.11 for the year 2021 and up to -$0.11 for 2022.
The average estimate suggests sales growth for the quarter will likely rise by 50.00% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $60k for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -62.00% below that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give MTNB a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Buy.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 5 analysts have assigned MTNB a recommendation rating as follows: 1 rate it as a Hold; 4 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Matinas BioPharma Holdings Inc. (MTNB) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that MTNB’s price is at present 37.12% off the SMA20 and 39.66% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 80.72, with weekly volatility standing at 9.07%. The indicator jumps to 6.40% when calculated based on the past 30 days. Matinas BioPharma Holdings Inc. (AMEX:MTNB)’s beta value is holding at 2.62, while the average true range (ATR) indicator is currently reading 0.06. Considering analysts have assigned the stock a price target range of $0.90-$3.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $2.38. Based on this estimate, we see that current price is roughly 14.29% off the estimated low and -185.71% off the forecast high. Investors will no doubt be excited to see the share price fall to $3.00, which is the median consensus price, and at that level MTNB would be -185.71% from current price.
Turning out attention to how the Matinas BioPharma Holdings Inc. stock has performed in comparison to its peers in the industry, here’s what we find: MTNB’s stock is 27.12% on the day and 51.45% in the past 12 months. Another comparison is with Omeros Corporation (OMER) whose stock price was up 1.86% in the last trading session, and has flourished 37.12% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.
An analysis of the Matinas BioPharma Holdings Inc. (AMEX:MTNB) stock in terms of its daily trading volume indicates that the 3-month average is 1.09 million.
Current records show that the company has 205.22M in outstanding shares. The insiders’ percentage holdings are 3.70% of outstanding shares while the percentage share held by institutions stands at 18.65%. But the -22.79% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.